Molecule News and Research

RSS

First time observing real-time molecular interplay within ribosome

The ribosome is a kind of factory for protein in the cell, and as such has long been a prime target for drug discovery. Now, a technological advance by a team at Weill Cornell Medical College is poised to revolutionize research in the field.

21 Mar 2007

Newly discovered peptide could help transplant for diabetes

A peptide developed by scientists at Weill Cornell Medical College may expand the availability and durability of islet cell transplant for patients with type-1 diabetes, which is characterized by a lack of these insulin-producing cells.

21 Mar 2007

Curry related compound shows promise against Kennedy's disease

Scientists who focus on the molecular signaling that underlies prostate cancer have discovered a compound that shows promise against a debilitating neurodegenerative condition known as Kennedy's disease, which is caused by a mutant gene.

21 Mar 2007

Scientists discover new approach for treating virus-induced lymphomas

Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi's sarcoma and primary effusion lymphoma (PEL). PELs are aggressive lymphomas with reported median survival time shorter than six months after diagnosis.

19 Mar 2007

Scientists decipher a signaling pathway crucially involved in Crohn's disease and ulcerative colitis

Inflammatory bowel diseases, such as Crohn's disease and Ulcerative Colitis, severely impair the lives of more than four million people worldwide. The development of effective therapies against these diseases requires an understanding of their underlying molecular mechanisms.

15 Mar 2007

Tykerb (lapatinib) - new anti-cancer treatment approved

The Food and Drug Administration (FDA) has approved Tykerb (lapatinib), a new targeted anti-cancer treatment, to be used in combination with capectabine (Xeloda), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit HER2 protein).

14 Mar 2007

Two novel therapies for multiple myeloma

Two novel biologics are currently being investigated for their potential benefit to multiple myeloma patients in separate ongoing clinical trials at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

14 Mar 2007

Disorderly protein brings order to cell division

The secret to the ability of a molecule critical for cell division to throw off the protein yoke that restrains its activity is the yoke itself - a disorderly molecule that seems to have a mind of its own, say investigators at St. Jude

13 Mar 2007

New drug target for herpes viruses

Scientists in the lab of Whitehead Institute Member Hidde Ploegh and the Harvard University lab of Rachelle Gaudet have solved the complex structure of a recently discovered protein that is found in a wide range of herpes viruses. This protein may prove to be a potential drug target.

11 Mar 2007

New drug target for herpes viruses

11 Mar 2007

Researchers show how endocrine cell types are produced in the pancreas

An international research team has identified the process by which pancreatic progenitor cells give rise to different endocrine cell types.

8 Mar 2007

Archemix granted two European patents

Archemix has announced today the issuance of two key, broad patents by the European Patent Office ("EPO"). The patents, EP 0 786 469 and EP 0 668 931, broadly cover methods for the identification and use of aptamers for therapeutic applications.

8 Mar 2007

Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling

Administering a small amount of a potent but potentially toxic anticancer agent along with nanoparticles loaded with a second anticancer agent produced a dramatic inhibition of tumor growth in normally intractable cancers. These findings suggest a new approach to treating malignancies such as pancreatic cancer and diffuse gastric cancer.

5 Mar 2007

Targeted nanoparticles image early tumors

A well-established fact in cancer therapy is that early tumor detection improves the odds that a patient will survive the disease. Now, using nanoparticles targeted to the tiny blood vessels that surround even the smallest tumors, researchers at the Siteman Center for Cancer Nanotechnology Excellence (CCNE) have developed a radioactive imaging agent that was able to identify human tumors in rabbits.

5 Mar 2007

Fox Chase Cancer Center and Cancer Research Technology initiate drug discovery collaboration

Cancer Research Technology Inc. (CRT Inc.) and Fox Chase Cancer Center have announce the initiation of an oncology-focused drug discovery collaboration.

1 Mar 2007

Key protein - claudin-1- for hepatitis C virus entry identified

For as many as 200 million people worldwide infected with hepatitis C, a leading cause of chronic liver disease, treatment options are only partially effective. But new research by Rockefeller University scientists points to a potential new target for better drugs: a key protein that resides in human liver cells that hepatitis C requires for entry.

27 Feb 2007

DNA 'cages' to deliver drugs

By combining DNA macromolecules with polymers containing iron, molecular 'cages' can be made: porous structures capable of carrying and delivering drugs or DNA-fragments.

26 Feb 2007

siRNA delivery into human T cells and primary cells with carbon-nanotube transporters

Short pieces of RNA, known as small interfering RNA (siRNA), have the potential to become a new class of anticancer drugs if researchers can solve the problem of how to deliver these fragile molecules to cancer cells.

26 Feb 2007

Research defines the cancer role for protein Gab-2

A protein known for its ability to "bridge" interactions between other cellular proteins may spur metastasis in breast cancer, the disease's deadliest stage, a study from Burnham Institute for Medical Research has found.

22 Feb 2007

microRNAs undergo molecular editing with significant physiological consequences

Tiny molecules called microRNAs, only 19 to 21 nucleotides in length, are able to effectively silence sometimes large sets of genes. They do this by specifically binding to and neutralizing another form of RNA called messenger RNA, responsible for conveying the information from genes to the cellular machinery that uses that information to create proteins, the building blocks of the body.

22 Feb 2007